| Old Articles: <Older 38601-38610 Newer> |
|---|
 |
The Motley Fool
October 20, 2009
Rick Aristotle Munarriz |
You Call This a Rebound, Gamers? The video game industry's flat September is a problem.   |
The Motley Fool
October 20, 2009
Anders Bylund |
Why Stock Exchanges Matter Does it really make a difference where your shares trade? |
The Motley Fool
October 20, 2009
David Lee Smith |
The Chinese May Be Drilling at Your Doorstep A Chinese offshore company may end up in the Gulf of Mexico, or Ghana, or just about anywhere. |
The Motley Fool
October 20, 2009
Brian Orelli |
All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug. |
The Motley Fool
October 20, 2009
Anders Bylund |
Why Won't Intel Kill AMD? Intel has handed a large market segment to AMD on a silver platter. Here's why. |
The Motley Fool
October 20, 2009
Alyce Lomax |
Hang On to Coach? Should investors bag shares of this luxury leader? |
The Motley Fool
October 20, 2009
Anders Bylund |
Where Does TI Go From Here? Up, Of Course Ride 'em, cowboy! A lean, mean Texas Instruments is ready to rock this rodeo. |
The Motley Fool
October 20, 2009
Robert Steyer |
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. |
The Motley Fool
October 20, 2009
Robert Steyer |
MGM Mirage: Partners Wanted The casino's biggest shareholder, Kirk Kerkorian, might seek additional investors. |
The Motley Fool
October 20, 2009
Brian Orelli |
Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses. |
| <Older 38601-38610 Newer> Return to current articles. |
